ARWR
Price
$12.06
Change
-$0.63 (-4.96%)
Updated
Apr 3 closing price
Capitalization
1.66B
34 days until earnings call
BCRX
Price
$7.07
Change
-$0.26 (-3.55%)
Updated
Apr 4, 12:02 PM (EDT)
Capitalization
1.53B
27 days until earnings call
Ad is loading...

ARWR vs BCRX

Header iconARWR vs BCRX Comparison
Open Charts ARWR vs BCRXBanner chart's image
Arrowhead Pharmaceuticals
Price$12.06
Change-$0.63 (-4.96%)
Volume$2.4M
Capitalization1.66B
BioCryst Pharmaceuticals
Price$7.07
Change-$0.26 (-3.55%)
Volume$3.68K
Capitalization1.53B
ARWR vs BCRX Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. BCRX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and BCRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARWR: $12.06 vs. BCRX: $7.33)
Brand notoriety: ARWR and BCRX are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 156% vs. BCRX: 90%
Market capitalization -- ARWR: $1.66B vs. BCRX: $1.53B
ARWR [@Biotechnology] is valued at $1.66B. BCRX’s [@Biotechnology] market capitalization is $1.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • BCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while BCRX’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 4 bearish.
  • BCRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ARWR and BCRX are a good buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а -12.61% price change this week, while BCRX (@Biotechnology) price change was -6.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

ARWR is expected to report earnings on May 08, 2025.

BCRX is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($1.66B) has a higher market cap than BCRX($1.53B). BCRX YTD gains are higher at: -2.527 vs. ARWR (-35.851). BCRX has higher annual earnings (EBITDA): 12.8M vs. ARWR (-580.69M). ARWR has more cash in the bank: 553M vs. BCRX (321M). ARWR has less debt than BCRX: ARWR (525M) vs BCRX (809M). BCRX has higher revenues than ARWR: BCRX (451M) vs ARWR (2.5M).
ARWRBCRXARWR / BCRX
Capitalization1.66B1.53B108%
EBITDA-580.69M12.8M-4,537%
Gain YTD-35.851-2.5271,419%
P/E RatioN/AN/A-
Revenue2.5M451M1%
Total Cash553M321M172%
Total Debt525M809M65%
FUNDAMENTALS RATINGS
ARWR vs BCRX: Fundamental Ratings
ARWR
BCRX
OUTLOOK RATING
1..100
5514
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9254
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5049

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (29) in the Biotechnology industry is significantly better than the same rating for ARWR (96). This means that BCRX’s stock grew significantly faster than ARWR’s over the last 12 months.

BCRX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as ARWR (100). This means that BCRX’s stock grew similarly to ARWR’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that BCRX’s stock grew similarly to ARWR’s over the last 12 months.

BCRX's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for ARWR (92). This means that BCRX’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for BCRX (100). This means that ARWR’s stock grew significantly faster than BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRBCRX
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 19 days ago
81%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWCCX56.26N/A
N/A
American Century Ultra® C
MFAIX24.78N/A
N/A
Morgan Stanley Inst Intl Advtg I
IMAIX9.38N/A
N/A
Macquarie Multi-Asset Income I
TFCCX19.39N/A
N/A
Touchstone Large Cap C
VCRQX13.89-0.08
-0.57%
NYLI CBRE Global Infrastructure Class R6

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-4.96%
DNLI - ARWR
56%
Loosely correlated
-6.91%
NTLA - ARWR
53%
Loosely correlated
-5.62%
BEAM - ARWR
50%
Loosely correlated
-10.93%
RGNX - ARWR
49%
Loosely correlated
-5.39%
CRNX - ARWR
47%
Loosely correlated
-8.03%
More